Despite initial hopes to the contrary, Novo Nordisk has said that semaglutide, the active ingredient for the weight loss jab Wegovy, does not slow Alzheimer’s, reports the BBC.
Researchers launched two large trials involving more than 3 800 people after reports that the medicine was having an impact in the real world.
But the studies showed that the GLP-1 drug, used to manage type 2 diabetes and obesity, made no difference compared with a placebo.
The disappointing results are due to be presented at an Alzheimer's disease conference next month and are yet to be published in a peer-reviewed journal.
Dr Susan Kohlhaas from Alzheimer’s Research UK said the results would be a blow for people affected by Alzheimer’s.
Martin Holst Lange, chief scientific officer and executive vice-president of R&D at Novo Nordisk, said: “Based on the significant unmet need in Alzheimer’s disease as well as a number of indicative data points, we felt we had a responsibility to explore semaglutide’s potential, despite a low likelihood of success.
“While it did not demonstrate efficacy in slowing the progression of Alzheimer’s, the extensive body of evidence supporting semaglutide continues to provide benefits for individuals with type 2 diabetes, obesity, and related comorbidities.”
The patients who took part in the Evoke trials were aged between 55 and 85 and had mild cognitive impairment or mild dementia due to Alzheimer’s disease.
Dementia progression was monitored and measured through tests and interviews.
Treatment with semaglutide resulted in improvement of Alzheimer’s-related biomarkers, but this did not translate into delaying progression of the disease.
Kohlhaas said: “These trial results are another reminder that Alzheimer’s is driven by several different biological processes. No single approach is likely to be enough.”
Fiona Carragher, chief policy and research officer at Alzheimer’s Society, said while the results were “very disappointing, no trial is wasted”.
“Every investigation helps us develop better drugs and design better trials in the future.”
There are currently more than 130 Alzheimer’s drugs in clinical trials, of which around 30 are in late-stage trials, the final step before they are considered by regulators.
BBC article – Obesity jab drug fails to slow Alzheimer's (Open access)
See more from MedicalBrief archives:
New dementia drugs still won’t be accessible to the poorest
Alzheimer’s Society calls for ‘failed’ dementia drug trials to be revisited